Assess the potential effects on the QT interval of 2 consecutive doses of ADASUVE
administered 2 hours apart, in relation to placebo and an active control in healthy
volunteers.
Phase:
Phase 4
Details
Lead Sponsor:
Alexza Pharmaceuticals, Inc.
Treatments:
Fluoroquinolones Loxapine Moxifloxacin Norgestimate, ethinyl estradiol drug combination